Drug Trial Radar · NCT01633541
Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
Last checked: Nov 19, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Mar 2012
Primary completion
Nov 6, 2021
Study completion Nov 6, 2021
Sponsor
- Lead sponsor
- University of Michigan Rogel Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 4, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate a new treatment approach for adults with advanced laryngeal cancer: induction chemotherapy with platinum and docetaxel plus AT-101. AT-101 is an investigational drug for the treatment of advanced cancer. It is hoped that the combination of this chemotherapy regimen will allow cancer patients to keep their voice box and to improve/maintain voice-related quality of life. The ultimate goal of this study is to prevent the surgery to remove subjects voice box.
Conditions
- Laryngeal Cancer
Interventions
AT-101Drug
Patients will receive AT-101 40 mg orally two times a day.
DocetaxelDrug
Docetaxel (Taxotere) 75 mg/m2
CisplatinDrug
Cisplatin 100 mg/m2
CarboplatinDrug
Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post TreatmentTime frame: Up to 3 months after end of treatment
- Progression-free SurvivalTime frame: Up to 3 years after randomization
- Overall Response Rate (ORR)Time frame: Up to approximately 60 days
- Percentage of Patients Experiencing Grade 3 or Higher Adverse Events.Time frame: Up to 3 years after end of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.